Crispr Therapeutics stock was tumbling Wednesday after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors. 

That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs). 

The…

LEAVE A REPLY

Please enter your comment!
Please enter your name here